Malaria – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23019IDB-L5

Select Item

Empower your strategies with our Malaria – Drugs In Development, 2024 report and make more profitable business decisions.

Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria, and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea, and vomiting. Treatment includes anti-malarial medicines.

The Malaria drugs in development market research report provide comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malaria and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Malaria
Key Targets
· Plasmodium falciparum Circumsporozoite Protein (CSP); Plasmodium falciparum Merozoite Surface Protein 1; Plasmodium falciparum 25 kDa Ookinete Surface Antigen; Plasmodium falciparum Non SERCA Type Ca2+ Transporting P-ATPase; Plasmodium falciparum Apical Membrane Antigen 1; Beta Hematin; Cytochrome bc1 Complex; 16S Ribosomal RNA; Dihydrofolate Reductase; and DNA
Key Mechanisms of Action
· Plasmodium falciparum Circumsporozoite Protein (CSP) Inhibitor; Plasmodium falciparum Non SERCA Type Ca2+ Transporting P-ATPase Inhibitor; Beta Hematin Inhibitor; Cytochrome bc1 Complex Inhibitor; DNA Inhibitor; Dihydroorotate Dehydrogenase Quinone Mitochondrial Inhibitor; Dihydrofolate Reductase Inhibitor; Basigin Inhibitor; 16S Ribosomal RNA Inhibitor; and Histone Lysine N Methyltransferase EHMT2 Inhibitor
Key Routes of Administration
· Oral; Intramuscular; Intravenous; Subcutaneous; Parenteral; Intradermal; Inhalational; Nasal; Suppository; and Transdermal
Key Molecule Types
· Small Molecule; Subunit Vaccine; Recombinant Vector Vaccine; Vaccine; Monoclonal Antibody; mRNA Vaccine; Live Attenuated Vaccine; Fusion Protein; DNA Vaccine; and Conjugate Vaccine
Major Companies
· Novartis AG; Eisai Co Ltd; GSK plc; Medicines for Malaria Venture; The National Institute of Allergy and Infectious Diseases; Vac4All SAS; University of Oxford; Sanaria Inc; US Army Medical Research & Materiel Command; and University of Cape Town

Scope

  • Therapeutics in Development: Covering 263 molecules, with 156 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Malaria therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Malaria pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Malaria treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

4SC AG
60 Degrees Pharmaceuticals Inc
AbbVie Inc
AchilleS Vaccines Srl
AliquantumRx Inc
Allergy Therapeutics Plc
Altimmune Inc
Antagen Pharmaceuticals Inc
Artificial Cell Technologies Inc
Atomwise Inc
AUM LifeTech Inc
Avalia Immunotherapies Ltd
Baseimmune Ltd
Bharat Biotech Ltd
Bill & Melinda Gates Medical Research Institute
Biomedical Primate Research Centre
BioNTech SE
Blue Water Biotech Inc
Brain-Gen LLC
Bristol-Myers Squibb Co
Burnet Institute
California Institute for Biomedical Research
Carna Biosciences Inc
Cascade Therapeutics Inc
Cellics Therapeutics Inc
Center for Infectious Disease Research
Central Drug Research Institute
Centre National de la Recherche Scientifique
Cesa Alliance SA
Chengdu WestGene Biopharma Co Ltd
Cilian AG
Collaborations Pharmaceuticals Inc
Crystec Ltd
Curevac NV
Daiichi Sankyo Co Ltd
Drexel University
East China University Of Science And Technology
Eisai Co Ltd
ElSohly Laboratories Inc
EpiVax Inc
Evotec SE
Expres2ion Biotechnologies ApS
Exscientia Plc
Ferrier Research Institute
Foundation For Neglected Disease Research
French National Institute of Health and Medical Research
George Washington University
Georgia Institute of Technology
GeoVax Labs Inc
Griffith University
GSK plc
Guangzhou Institute of Biomedicine and Health
Guru Nanak Dev University College
Hannover Medical School
Hawaii Biotech Inc
Helmholtz Centre for Infection Research
Ibex Bioscience Inc
Ichor Medical Systems Inc
IGM Biosciences Inc
Immune Modulation Inc
Imperial College London
Imutex Ltd
IMV Inc
Indoco Remedies Ltd
Innovex Therapeutics SL
International Centre for Genetic Engineering and Biotechnology
IPCA Laboratories Ltd
Jacobus Pharmaceutical Co Inc
Jiangsu Pacific Meinuoke Bio-Pharmarceutical Co Ltd
Johns Hopkins University
Johnson & Johnson
Kainomyx Inc
KELTIC Pharma Therapeutics Ltd
Kymab Ltd
Leiden University Medical Center
Loyola University Chicago
Luckwel Pharmaceuticals Inc
Lumen Bioscience Inc
Lyndra Therapeutics Inc.
Mahidol University
Manuka Inc
Massachusetts Institute of Technology
Medicines for Malaria Venture
MedinCell SA
MediSynergics LLC
MegaNano BioTech Inc
Merck & Co Inc
Merck KGaA
Microbiotix Inc
Mitsubishi Tanabe Pharma Corp
Moderna Inc
Modus Therapeutics AB
Mycosynthetix Inc
Mymetics Corp
Nanyang Technological University
National University of Singapore
Naval Medical Research Center
Nobelpharma Co Ltd
Northeastern University
Novartis AG
Ocean Biomedical Inc.
Okayama University
Oregon State University
Osivax SAS
Otsuka Pharmaceutical Co Ltd
PATH
PATH Malaria Vaccine Initiative
Pfizer Inc
PGTx Ltd
Portland State University
Protein Potential LLC
Purdue University
QIMR Berghofer Medical Research Institute
Radboud University
Replikins Ltd
Rhode Island Hospital
RIKEN
Rodos BioTarget GmbH
Sanaria Inc
Sanofi
Serum Institute of India Pvt Ltd
Shanghai Institute of Materia Medica Chinese Academy of Sciences
Shin Poong Pharm Co Ltd
Shionogi & Co Ltd
Spanish Foundation for Science and Technology
Stanford University
Statens Serum Institut
Stemirna Therapeutics Ltd
Sumaya Biotech GmbH & Co KG
Sumitomo Pharma Co Ltd
Takeda Pharmaceutical Co Ltd
Tandem Nano Ltd
Tarsus Pharmaceuticals Inc
Texas A&M University
The Francis Crick Institute Ltd
The National Institute of Allergy and Infectious Diseases
The Walter and Eliza Hall Institute of Medical Research
Theravectys SA
U.S. Department of Veterans Affairs
UCB SA
University of Auckland
University of California San Diego
University of Campinas Brazil
University of Cape Town
University of Copenhagen
University of Edinburgh
University of Florida
University of Georgia
University of Illinois at Chicago
University of Kansas
University of Lausanne
University of Lyon
University of Mississippi
University of Oklahoma
University of Oxford
University of Queensland
University of Rochester
University of Sao Paulo
University of Sciences Techniques and Technologies Bamako
University of Washington
US Army Medical Research & Materiel Command
Uvax Bio LLC
Vac4All SAS
Vanderbilt University
VicuTec Biologicals GmbH
Virginia Polytechnic Institute and State University
VLP Biotech Inc
VLP Therapeutics LLC
Walter Reed Army Institute of Research
Washington University in St Louis
Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Malaria reports
Pharmaceuticals
New
Pharma M&A Deals H1 2026 - Top Themes: Strategic Intelligence
$495 | July 2026
Pharmaceuticals
New
Epilepsy (Adults) in Major Markets: Disease Management, Epidemiology, Pipeline Assessment,…
$17,995 | July 2026
Pharmaceuticals
New
Melanoma: Epidemiology Forecast to 2035
$9,995 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Malaria – Drugs In Development, 2024 in real time.

  • Access a live Malaria – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more